Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 3/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | POLG | P54098 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Psi-352666 SCHEMBL12849780 | 1.00 | TGM2 (0.57) | TGM2POLBFUT5KRASP2RY6 | |
| Psi-352666 SCHEMBL18061810 | 1.00 | TGM2 (0.57) | TGM2POLBFUT5KRASP2RY6 | |
| Psi-352666 SCHEMBL15892588 | 1.00 | TGM2 (0.57) | TGM2POLBFUT5KRASP2RY6 | |
| Psi-352666 SCHEMBL12878134 | 1.00 | TGM2 (0.57) | TGM2POLBFUT5KRASP2RY6 | |
| SCHEMBL12849789 | 0.99 | TGM2 (0.58) | TGM2POLBFUT5KRASP2RY6 | |
| SCHEMBL12878145 | 0.99 | TGM2 (0.58) | TGM2POLBFUT5KRASP2RY6 | |
| SCHEMBL12799375 | 0.99 | TGM2 (0.58) | TGM2POLBFUT5KRASP2RY6 | |
| SCHEMBL18061560 | 0.99 | TGM2 (0.58) | TGM2POLBFUT5KRASP2RY6 | |
| SCHEMBL25844101 | 0.93 | TGM2 (0.57) | TGM2POLBFUT5KRASP2RY6 | |
| SCHEMBL790130 | 0.93 | POLB (0.54) | TGM2POLBFUT5KRASP2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
| US-8415322-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415322-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120245335-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2012-09-27 | — | — | US | disclosed |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7429572-B2 | Modified fluorinated nucleoside analogues | PHARMASSET, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | TGM2 3029/4885POLB 1957/4885FUT5 87/4885 |
| US-20120245335-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | TGM2 3029/4885POLB 1957/4885FUT5 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.